All In Biotech

Drug Trial Radar · NCT07589400

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B

A Multicenter, Randomized, Double-blind, Multiple Ascending Dose, Placebo-controlled Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-associated Steatotic Liver Disease Complicated With Chronic Hepatitis B.

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

Mar 30, 2027

Study completion Jun 30, 2027

Sponsor

Sponsor type
Industry
First posted
May 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase Ib, multicenter randomized, double-blind, dose-escalation, placebo-controlled trial designed to evaluate the safety, tolerability, PK, and PD profiles of multiple-dose ACT500 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) complicated with chronic hepatitis B (CHB). The trial plans to enroll 24 participants with MASLD complicated with CHB across three dose cohorts initially, each consisting of 8 participants who will receive oral ACT500 tablets once daily.

Conditions

  • Metabolic Dysfunction-associated Steatotic Liver Disease
  • Chronic Hepatitis b

Interventions

  • ACT500 TabletsDrug

    Once daily, orally

  • ACT500 TabletsDrug

    Once daily, orally

  • ACT500 TabletsDrug

    Once daily, orally

  • ACT500 Placebo TabletsDrug

    Once daily, orally

  • ACT500 Placebo TabletsDrug

    Once daily, orally

  • ACT500 Placebo TabletsDrug

    Once daily, orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventTime frame: Day1-112
  2. Serious Adverse EventTime frame: Day1-112
  3. body temperatureTime frame: Day1,14,29,56,84,112
  4. breatheTime frame: Day1,14,29,56,84,112
  5. pulseTime frame: Day1,14,29,56,84,112
  6. blood pressureTime frame: Day1,14,29,56,84,112
  7. Number of Participants with Abnormal Laboratory Parameters FindingsTime frame: Day1,14,29,56,84,112
  8. Number of participants with clinically significant change from baseline in physical examinationTime frame: Day1,14,29,56,84,112
  9. PR IntervalTime frame: Day14,29,56,84,112
  10. QRS IntervalTime frame: Day14,29,56,84,112
  11. QT IntervalTime frame: Day14,29,56,84,112
  12. QTc IntervalTime frame: Day14,29,56,84,112

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, China

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, China

  • The First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, China

  • Xiamen Hospital of Traditional Chinese Medicine

    Xiamen, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.